Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jade Biosciences, Inc. (JBIO : NSDQ)

• Company Description    Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $19.45 Daily Weekly Monthly 20 Day Moving Average: 695,030 shares Shares Outstanding: 63.60 (millions) Market Capitalization: $1,236.97 (millions) Beta: 1.45 52 Week High: $28.00 52 Week Low: $6.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.98% -12.35% 12 Week 25.24% 22.59% Year To Date 26.05% 12.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 Crescent Street Building 23 Suite 105 - Waltham,MA 02453 USA ph: 781-312-3013 fax: - ir@jadebiosciences.com https://jadebiosciences.com

• General Corporate Information    Officers Tom Frohlich - Chief Executive Officer & Director Eric Dobmeier - Chairman Bradford Dahms - Chief Financial Officer and Treasurer Chris Cain - Director Lawrence Klein - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 008064206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 63.60 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.45 Market Capitalization: $1,236.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.81 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 11.63% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -49.11 03/31/26 - -51.34 12/31/25 - -46.55 ROA 06/30/26 - -45.62 03/31/26 - -47.32 12/31/25 - -42.99 Current Ratio 06/30/26 - 14.93 03/31/26 - 14.29 12/31/25 - 21.09 Quick Ratio 06/30/26 - 14.93 03/31/26 - 14.29 12/31/25 - 21.09 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 6.92 03/31/26 - 6.01 12/31/25 - 6.74 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©